Snake bite and antivenom treatment
Conditions
Interventions
The enrolled patients will be treated with snake antiserum (lyophilized polyvalent enzyme-refined, manufactured in India by Vins Bioproduct Limited, Mumbai or Bharat Serums and Vaccines Limited, Amber
Sponsors
Prof SAM Kularatne
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with proven common krait bites (with an offending snake or with clear clinical evidence of common krait envenoming) 2. Older than 12 years of age 3. Presence of features of envenoming with indications for antivenom
Exclusion criteria
Exclusion criteria: 1. Patients who had snake anti venom treatment earlier. 2. Patients who are already having or had any neurological diseases e.g. myasthenia gravis, infective polyneuropathy, Alzheimer disease etc. 3. Patients who presented with ingestion of alcohol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The duration of mechanical ventilation [Time in hours from the onset of intubation to extubation] | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of patients needed mechanical ventilation 2. Time gap from antivenom treatment to intubation and ventilation 3. Time taken to complete reversal of neurotoxic signs (Ptosis, Opthalmoplegia, Neck flexon) 4. Incidence of secondary complications 5. Duration of ICU stay 6. Duration of hospital stay [From the time of recruitment] | — |
Countries
Sri Lanka
Contacts
Public ContactProf SAM Kularatne
Professor in Medicine,
Outcome results
None listed